Gene Therapy Start-Up Sangamo Bio-Sciences
Country: USA | Funding: $522.1M
Sangamo is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of engineered zinc finger DNA-binding proteins (ZFPs) as novel ZFP Therapeutics targeting various monogenic and infectious diseases with unmet medical needs.
Sangamo Therapeutics, Inc. | Pioneering Genetic Cures
Who Are Sangamo Bio-Sciences?
Sangamo Bio-Sciences is a leading biotechnology company specializing in gene therapy, gene editing, and cell therapy. The company is focused on developing innovative treatments for genetic diseases and disorders by utilizing its proprietary technologies, including zinc finger nucleases (ZFNs), TALE nucleases, and CRISPR/Cas9 gene editing systems.
Sangamo Bio-Sciences was founded in 1995 by Edward Lanphier, a biotechnology industry veteran. The company’s first breakthrough came in 1996 when it developed ZFN technology, a tool that can target specific genes in a patient’s DNA and modify them. This technology revolutionized the field of gene therapy and opened up new possibilities for treating genetic diseases.
Since then, the company has continued to advance its technology platform, expanding its focus to include cell therapy and gene editing. In 2015, Sangamo Bio-Sciences acquired TxCell, a French biotechnology company specializing in cell therapy, to broaden its expertise in the field. The acquisition enabled Sangamo Bio-Sciences to accelerate its efforts to develop CAR-T cell therapies, a promising new approach to cancer treatment.
Sangamo Bio-Sciences’ gene therapy approach involves introducing functional copies of a faulty gene into a patient’s cells to replace the defective ones. Gene editing, on the other hand, involves making precise changes to a patient’s DNA to correct or delete a faulty gene. The company’s cell therapy approach involves modifying a patient’s immune cells to target and destroy cancer cells.
One of Sangamo Bio-Sciences’ most promising therapies is SB-913, a gene therapy for Hunter syndrome, a rare genetic disorder that affects approximately 1 in 100,000 males. The therapy involves using a viral vector to introduce a functional copy of the gene that is missing or defective in patients with Hunter syndrome. The company has reported positive results from a Phase 1/2 clinical trial of SB-913, with patients showing sustained levels of the missing enzyme and a reduction in symptoms.
Sangamo Bio-Sciences has also made significant progress in developing gene editing therapies for a range of genetic diseases, including sickle cell disease, beta-thalassemia, and Huntington’s disease. The company’s proprietary In Vivo Protein Replacement Platform (IVPRP) enables the delivery of gene editing enzymes directly into a patient’s liver, allowing for precise editing of genes responsible for these diseases.
In addition to its proprietary technologies, Sangamo Bio-Sciences has also formed partnerships with other biotechnology companies and academic institutions to advance its research and development efforts. For example, the company has partnered with Pfizer to develop gene therapies for hemophilia, a genetic disorder that affects blood clotting.
Sangamo Bio-Sciences’ innovative approach to gene therapy, gene editing, and cell therapy has earned it a reputation as a leader in the field. The company has a strong pipeline of therapies in development and is well-positioned to bring innovative treatments to patients with genetic diseases and disorders. With continued investment in research and development, Sangamo Bio-Sciences is poised to make a significant impact on the field of gene therapy and revolutionize the treatment of genetic diseases.
How Does Sangamo Bio-Science Market Their Business?
Sangamo Bio-Sciences markets its business through a combination of traditional and modern marketing methods. Here are some ways the company promotes its products and services:
- Industry Conferences and Events: Sangamo Bio-Sciences attends and sponsors various conferences and events related to gene therapy, gene editing, and cell therapy. These events provide the company with the opportunity to showcase its technology and expertise, network with potential partners and customers, and stay up-to-date on the latest developments in the industry.
- Scientific Publications: Sangamo Bio-Sciences regularly publishes its research findings in scientific journals and presents at scientific conferences. This helps to establish the company as a thought leader in the field and promotes its technology to other researchers and potential partners.
- Digital Marketing: The company maintains an active website, social media profiles, and email newsletters to communicate with its customers, investors, and stakeholders. The website provides detailed information about the company’s technology, products, and services. Social media profiles are used to share news, research findings, and industry insights.
- Direct Sales and Partnerships: Sangamo Bio-Sciences has a dedicated sales team that markets its products and services directly to healthcare providers, researchers, and institutions. The company also partners with pharmaceutical companies, academic institutions, and government agencies to collaborate on research and development projects.
- Investor Relations: The company maintains an active investor relations program to communicate with its investors and potential investors. This includes regular earnings calls, presentations at investor conferences, and investor roadshows.
In summary, Sangamo Bio-Sciences markets its business through a variety of channels, including industry conferences, scientific publications, digital marketing, direct sales, partnerships, and investor relations. By leveraging these channels, the company is able to build its brand, showcase its technology, and attract new customers, partners, and investors.
If you found this article insightful and need similar content for your site please contact us using the button below:
#SangamoBioSciences #genetherapy #cellteraphy #cellandtherapyai #cgtai #biotechnology #biotechnologymarketing #biotechnologywriting #cgtaiwriting
Renata is a businesswoman and published author. She primarily focuses on Digital Marketing, Content Writing, Website Design, Develo[pment, SEO, and Domain Brokering.
Renata is also the Editor of 'iRenata.com', 'UK Website Designers', 'Cymru Marketing Journal', 'UK Domain Brokers' and 'Disability UK' Online Magazine.
Renata offers several services for startups and SMEs.
Renata has a large network of over 10K connections on LinkedIn, compromising of Directors, CEOs, Millionaires, Billionaires, and Royalty. https://www.linkedin.com/in/renata-b-48025811/
Leave a Reply
You must be logged in to post a comment.